© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 20, 1576-1578,
October 16, 2002
© 2002 Oxford University Press
BRIEF COMMUNICATION |
Serum Proteomic Patterns for Detection of Prostate Cancer
Affiliations of authors: E. F. Petricoin III, P. S. Hackett, L. Wiegand, K. Wood, Food and Drug Administration (FDA)–National Cancer Institute (NCI) Clinical Proteomics Program, Department of Therapeutic Proteins/Center for Biologics Evaluation and Research (CBER), FDA, Bethesda, MD; D. K. Ornstein, Division of Urology, University of North Carolina, Chapel Hill; C. P. Paweletz, FDA–NCI Clinical Proteomics Program, Department of Therapeutic Proteins/CBER and Laboratory of Pathology, Center for Cancer Research (CCR), NCI, National Institutes of Health (NIH), Bethesda, and Department of Chemistry, Georgetown University, Washington, DC; A. Ardekani, FDA–NCI Clinical Proteomics Program, Department of Therapeutic Proteins/CBER Laboratory of Pathology, CCR, NCI, NIH; B. A. Hitt, P. J. Levine, Correlogic Systems, Inc., Bethesda; A. Velassco, C. Trucco, Department of Urology, Catholic University of Chile, Santiago; C. B. Simone, Simone Protective Cancer Institute, Lawrenceville, NJ; W. M. Linehan, Urologic Oncology Branch, NCI, NIH; M. R. Emmert-Buck, E. C. Kohn, L. A. Liotta, FDA–NCI Clinical Proteomics Program, Laboratory of Pathology, CCR, NCI, NIH; S. M. Steinberg, Biostatistics and Data Management Section, CCR, NCI, NIH.
Correspondence to: Emanuel F. Petricoin III, Ph.D., Bldg. 29A, Rm. 2D12, 8800 Rockville Pike, Bethesda, MD 20892 (e-mail: petricoin{at}cber.fda.gov).
ABSTRACT
Pathologic states within the prostate may be reflected by changes in serum proteomic patterns. To test this hypothesis, we analyzed serum proteomic mass spectra with a bioinformatics tool to reveal the most fit pattern that discriminated the training set of sera of men with a histopathologic diagnosis of prostate cancer (serum prostate-specific antigen [PSA] 
4 ng/mL) from those men without prostate cancer (serum PSA level <1 ng/mL). Mass spectra of blinded sera (N = 266) from a test set derived from men with prostate cancer or men without prostate cancer were matched against the discriminating pattern revealed by the training set. A predicted diagnosis of benign disease or cancer was rendered based on similarity to the discriminating pattern discovered from the training set. The proteomic pattern correctly predicted 36 (95%, 95% confidence interval [CI] = 82% to 99%) of 38 patients with prostate cancer, while 177 (78%, 95% CI = 72% to 83%) of 228 patients were correctly classified as having benign conditions. For men with marginally elevated PSA levels (4–10 ng/mL; n = 137), the specificity was 71%. If validated in future series, serum proteomic pattern diagnostics may be of value in deciding whether to perform a biopsy on a man with an elevated PSA level.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. H. Moretz III, C. G. Gourin, D. J. Terris, Z.-S. Xia, Z. Liu, P. M. Weinberger, E. Chin, and B.-L. Adam Detection of Papillary Thyroid Carcinoma With Serum Protein Profile Analysis Arch Otolaryngol Head Neck Surg, February 1, 2008; 134(2): 198 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. McLerran, W. E. Grizzle, Z. Feng, W. L. Bigbee, L. L. Banez, L. H. Cazares, D. W. Chan, J. Diaz, E. Izbicka, J. Kagan, et al. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias Clin. Chem., January 1, 2008; 54(1): 44 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Gourin, W. H. Moretz III, P. M. Weinberger, Z.-S. Xia, Z. Liu, D. J. Terris, and B.-L. Adam Serum Protein Profile Analysis Following Definitive Treatment in Patients With Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, November 1, 2007; 133(11): 1125 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Hammoud, L. Dobrolecki, K. A. Kesler, E. Rahmani, K. Rieger, L. H. Malkas, and R. J. Hickey Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern Ann. Thorac. Surg., August 1, 2007; 84(2): 384 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Tsao, G. Liu, and F. A. Shepherd Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap? J Natl Cancer Inst, June 6, 2007; 99(11): 826 - 827. [Full Text] [PDF]
|
|
|
|
|
|
K. Yanagisawa, S. Tomida, Y. Shimada, Y. Yatabe, T. Mitsudomi, and T. Takahashi A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non-Small-Cell Lung Cancer J Natl Cancer Inst, June 6, 2007; 99(11): 858 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gross, I. Top, I. Laux, J. Katz, J. Curran, C. Tindell, and D. Agus {beta}-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1979 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sardana, J. Marshall, and E. P. Diamandis Discovery of Candidate Tumor Markers for Prostate Cancer via Proteomic Analysis of Cell Culture-Conditioned Medium Clin. Chem., March 1, 2007; 53(3): 429 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Azad, N. Rasool, C. M. Annunziata, L. Minasian, G. Whiteley, and E. C. Kohn Proteomics in Clinical Trials and Practice: Present Uses and Future Promise Mol. Cell. Proteomics, October 1, 2006; 5(10): 1819 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Gourin, Z.-S. Xia, Y. Han, A. M. French, A. K. O'Rourke, D. J. Terris, and B.-L. Adam Serum protein profile analysis in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 390 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chung, D. Clifford, M. Buckley, and R. C. Baxter Novel Biomarkers of Human Growth Hormone Action from Serum Proteomic Profiling Using Protein Chip Mass Spectrometry J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 671 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. EVERLEY and B. R. ZETTER Proteomics in Tumor Progression and Metastasis Ann. N.Y. Acad. Sci., November 1, 2005; 1059(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Ressom, R. S. Varghese, M. Abdel-Hamid, S. A.-L. Eissa, D. Saha, L. Goldman, E. F. Petricoin, T. P. Conrads, T. D. Veenstra, C. A. Loffredo, et al. Analysis of mass spectral serum profiles for biomarker selection Bioinformatics, November 1, 2005; 21(21): 4039 - 4045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Lopez, A. Mikulskis, S. Kuzdzal, D. A. Bennett, J. Kelly, E. Golenko, J. DiCesare, E. Denoyer, W. F. Patton, R. Ediger, et al. High-Resolution Serum Proteomic Profiling of Alzheimer Disease Samples Reveals Disease-Specific, Carrier-Protein-Bound Mass Signatures Clin. Chem., October 1, 2005; 51(10): 1946 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mian, S. Ugurel, E. Parkinson, I. Schlenzka, I. Dryden, L. Lancashire, G. Ball, C. Creaser, R. Rees, and D. Schadendorf Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients J. Clin. Oncol., August 1, 2005; 23(22): 5088 - 5093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F M Brouwers, E F Petricoin III, L Ksinantova, J Breza, V Rajapakse, S Ross, D Johann, M Mannelli, B L Shulkin, R Kvetnansky, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma Endocr. Relat. Cancer, June 1, 2005; 12(2): 263 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Meyerson and D. Carbone Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted Therapy J. Clin. Oncol., May 10, 2005; 23(14): 3219 - 3226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wright, D. K. Han, and R. Aebersold Mass Spectrometry-based Expression Profiling of Clinical Prostate Cancer Mol. Cell. Proteomics, April 1, 2005; 4(4): 545 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Grizzle, D. G. Bostwick, H. Burke, O. W. Tawfik, D. McGregor, J. Cohn, and R. Lieberman Biomarkers in Prostate Cancer Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 196 - 204. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Liotta, M. Lowenthal, A. Mehta, T. P. Conrads, T. D. Veenstra, D. A. Fishman, and E. F. Petricoin III Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data J Natl Cancer Inst, February 16, 2005; 97(4): 310 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Malik, M. D. Ward, S. K. Gupta, M. W. Trosset, W. E. Grizzle, B.-L. Adam, J. I. Diaz, and O. J. Semmes Serum Levels of an Isoform of Apolipoprotein A-II as a Potential Marker for Prostate Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1073 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Posadas, F. Simpkins, L. A. Liotta, C. MacDonald, and E. C. Kohn Proteomic analysis for the early detection and rational treatment of cancer--realistic hope? Ann. Onc., January 1, 2005; 16(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Coombes Analysis of Mass Spectrometry Profiles of the Serum Proteome Clin. Chem., January 1, 2005; 51(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
O. J. Semmes, Z. Feng, B.-L. Adam, L. L. Banez, W. L. Bigbee, D. Campos, L. H. Cazares, D. W. Chan, W. E. Grizzle, E. Izbicka, et al. Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility Clin. Chem., January 1, 2005; 51(1): 102 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hood, J. R. Heath, M. E. Phelps, and B. Lin Systems Biology and New Technologies Enable Predictive and Preventative Medicine Science, October 22, 2004; 306(5696): 640 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Radulovic, S. Jelveh, S. Ryu, T. G. Hamilton, E. Foss, Y. Mao, and A. Emili Informatics Platform for Global Proteomic Profiling and Biomarker Discovery Using Liquid Chromatography-Tandem Mass Spectrometry Mol. Cell. Proteomics, October 1, 2004; 3(10): 984 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, R. C. Bast Jr., Y. Yu, J. Li, L. J. Sokoll, A. J. Rai, J. M. Rosenzweig, B. Cameron, Y. Y. Wang, X.-Y. Meng, et al. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer Cancer Res., August 15, 2004; 64(16): 5882 - 5890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Grizzle, S. Meleth, E. F. Petricoin, and L. A. Liotta Clarification in the Point/Counterpoint Discussion Related to Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Identification of Patients with Adenocarcinomas of the Prostate * Proteomic Pattern Complexity Reveals a Rich and Uncharted Continent of Biomarkers Clin. Chem., August 1, 2004; 50(8): 1475 - 1477. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Soltys, Q.-T. Le, G. Shi, R. Tibshirani, A. J. Giaccia, and A. C. Koong The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers Clin. Cancer Res., July 15, 2004; 10(14): 4806 - 4812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Tricoli, M. Schoenfeldt, and B. A. Conley Detection of Prostate Cancer and Predicting Progression: Current and Future Diagnostic Markers Clin. Cancer Res., June 15, 2004; 10(12): 3943 - 3953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. JOHANN JR., M. D. MCGUIGAN, A. R. PATEL, S. TOMOV, S. ROSS, T. P. CONRADS, T. D. VEENSTRA, D. A. FISHMAN, G. R. WHITELEY, E. F. PETRICOIN III, et al. Clinical Proteomics and Biomarker Discovery Ann. N.Y. Acad. Sci., June 1, 2004; 1022(1): 295 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Cristea, S. J. Gaskell, and A. D. Whetton Proteomics techniques and their application to hematology Blood, May 15, 2004; 103(10): 3624 - 3634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Xiao, B. T. Luke, G. Izmirlian, A. Umar, P. M. Lynch, R. K. S. Phillips, S. Patterson, T. P. Conrads, T. D. Veenstra, P. Greenwald, et al. Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors Cancer Res., April 15, 2004; 64(8): 2904 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool: Opportunities and Potential Limitations Mol. Cell. Proteomics, April 1, 2004; 3(4): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential Problems J Natl Cancer Inst, March 3, 2004; 96(5): 353 - 356. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Wadsworth, K. D. Somers, L. H. Cazares, G. Malik, B.-L. Adam, B. C. Stack Jr., G. L. Wright Jr., and O. J. Semmes Serum Protein Profiles to Identify Head and Neck Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1625 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Wilson The Promise of Disease Proteomics: Faster Detection, Diagnosis, and Drug Development Ann Intern Med, February 17, 2004; 140(4): 317 - 319. [Full Text] [PDF]
|
|
|
|
|
|
D. H. Geho, E. F. Petricoin, and L. A. Liotta Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer: Commentary re S. A. Schwartz et al., Protein Profiling in Brain Tumors Using Mass Spectrometry: Feasibility of a New Technique for the Analysis of Protein Expression. Clin. Cancer Res., 10: 981-987, 2004. Clin. Cancer Res., February 1, 2004; 10(3): 825 - 827. [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, Z. Zhang, N. White, J. Rosenzweig, N. Fedarko, S. Jagannath, M. I. Canto, C. J. Yeo, D. W. Chan, and M. Goggins Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry Clin. Cancer Res., February 1, 2004; 10(3): 860 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Martin, D. R. Gifford, M. E. Wright, A. Keller, E. Yi, D. R. Goodlett, R. Aebersold, and P. S. Nelson Quantitative Proteomic Analysis of Proteins Released by Neoplastic Prostate Epithelium Cancer Res., January 1, 2004; 64(1): 347 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Wadsworth, K. D. Somers, B. C. Stack Jr, L. Cazares, G. Malik, B.-L. Adam, G. L. Wright Jr, and O. J. Semmes Identification of Patients With Head and Neck Cancer Using Serum Protein Profiles Arch Otolaryngol Head Neck Surg, January 1, 2004; 130(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Petricoin, V. Rajapaske, E. H. Herman, A. M. Arekani, S. Ross, D. Johann, A. Knapton, J. Zhang, B. A. Hitt, T. P. Conrads, et al. Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection Toxicol Pathol, January 1, 2004; 32(1_suppl): 122 - 130. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Rogers, P. Clarke, J. Noble, N. P. Munro, A. Paul, P. J. Selby, and R. E. Banks Proteomic Profiling of Urinary Proteins in Renal Cancer by Surface Enhanced Laser Desorption Ionization and Neural-Network Analysis: Identification of Key Issues Affecting Potential Clinical Utility Cancer Res., October 15, 2003; 63(20): 6971 - 6983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-E. Taplin and P. W. Kantoff The Ingredients for Prostate Cancer Nomograms: The Addition of Biomarkers Sets the Table for Future Recipes J. Clin. Oncol., October 1, 2003; 21(19): 3552 - 3553. [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics? Clin. Chem., August 1, 2003; 49(8): 1272 - 1275. [Full Text] [PDF]
|
|
|
|
|
|
E. Petricoin III and L. A. Liotta The Vision for a New Diagnostic Paradigm Clin. Chem., August 1, 2003; 49(8): 1276 - 1278. [Full Text] [PDF]
|
|
|
|
|
|
B. Ye, D. W. Cramer, S. J. Skates, S. P. Gygi, V. Pratomo, L. Fu, N. K. Horick, L. J. Licklider, J. O. Schorge, R. S. Berkowitz, et al. Haptoglobin-{alpha} Subunit As Potential Serum Biomarker in Ovarian Cancer: Identification and Characterization Using Proteomic Profiling and Mass Spectrometry Clin. Cancer Res., August 1, 2003; 9(8): 2904 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, J. A. O'Shaughnessy, G. B. Gordon, E. T. Hawk, and C. C. Sigman Counterpoint: Because Some Surrogate End Point Biomarkers Measure the Neoplastic Process They Will Have High Utility in the Development of Cancer Chemopreventive Agents against Sporadic Cancers Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 593 - 596. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Celis, P. Gromov, I. Gromova, J. M. A. Moreira, T. Cabezon, N. Ambartsumian, M. Grigorian, E. Lukanidin, P. thor Straten, P. Guldberg, et al. Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research Mol. Cell. Proteomics, June 1, 2003; 2(6): 369 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Baker The Central Role of Receiver Operating Characteristic (ROC) Curves in Evaluating Tests for the Early Detection of Cancer J Natl Cancer Inst, April 2, 2003; 95(7): 511 - 515. [Full Text] [PDF]
|
|
|
|
|
|
E. F. Petricoin and L. A. Liotta Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection Clin. Chem., April 1, 2003; 49(4): 533 - 534. [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Re: Serum Proteomic Patterns for Detection of Prostate Cancer J Natl Cancer Inst, March 19, 2003; 95(6): 489 - 489. [Full Text] [PDF]
|
|
|
|
|
|
E. F. Petricoin III and L. A. Liotta RESPONSE: Re: Serum Proteomic Patterns for Detection of Prostate Cancer J Natl Cancer Inst, March 19, 2003; 95(6): 490 - 491. [Full Text] [PDF]
|
|